Related Experiment Video
Updated: Apr 18, 2026
08:34
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
21.3K
Accelerated hypofractioned postoperative radiotherapy for prostate cancer: a prospective phase I/II study
A Gladwish1, A Loblaw2, P Cheung1
1Department of Radiation Oncology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|January 12, 2015
Summary
This study shows that hypofractionated radiotherapy after prostatectomy is well-tolerated, with low toxicity and good initial prostate-specific antigen (PSA) control. Further research is needed for long-term outcomes.
Area of Science:
- Oncology
- Radiation Oncology
- Urology
Background:
- Post-prostatectomy radiotherapy is a standard treatment for some patients.
- Hypofractionation, delivering higher doses over fewer fractions, is being explored to improve treatment efficiency.
- Assessing toxicity and quality of life is crucial for evaluating new radiotherapy schedules.
Purpose of the Study:
- To evaluate the safety and efficacy of a hypofractionated radiotherapy schedule in patients after prostatectomy.
- To assess acute and late toxicity, quality of life, and prostate-specific antigen (PSA) control.
Main Methods:
- A single-institution, phase I/II study enrolled 30 patients requiring post-prostatectomy radiotherapy.
- Patients received 51 Gy in 17 daily fractions to the prostate bed.
- Toxicity was assessed using NCI CTCAE v3.0, quality of life with E-PICS, and PSA levels were monitored.
Main Results:
- The median follow-up was 24 months. Most patients had Gleason 7 disease and positive surgical margins.
- Over 80% experienced grade 1 acute toxicity; only 6% had grade 2/3 late toxicity.
- Quality of life scores were favorable, and 17% of patients experienced PSA failure.
Conclusions:
- Hypofractionated postoperative prostate radiotherapy is well-tolerated with acceptable toxicity and quality of life.
- Initial PSA control appears promising.
- Larger studies with longer follow-up are required to confirm these findings.
